Virtual pharmacist MedAdvisor draws investor attention amid M&A chatter
The pharmacy software business boasts a star studded shareholder register and exposure to one of the hottest trends in the market - miracle weight loss drug Ozempic.
With a shareholder register featuring one of the world's most storied private equity firms, a $5 billion dual-listed chemist wholesaler and, unusually, the powerful Pharmacy Guild, software business MedAdvisor has been on the radar of investors at the smaller end of the ASX all year.
The stock has more than doubled over the past 12 months, in part due to its exposure one of the biggest themes in the market at the moment - weight loss drugs like Ozempic, but also due to expectations it could be involved in corporate activity.
This week, the noise around the business got louder when one of its shareholders, New Zealand based EBOS Group, doubled its stake in the company to 9.8%.
“Given its platform and its extensive patient and pharmacy reach, I wouldn’t be surprised to see it be a takeover target for a US industry player,” DMX Asset Management portfolio manager Steven McCarthy, who holds shares of MedAdvisor, told Capital Brief.
